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Abstract
Global molecular profiling of cancers has shown broad
utility in delineating pathways and processes under-
lying disease, in predicting prognosis and response to
therapy, and in suggesting novel treatments. To gain
further insights from such data, we have integrated and
analyzed a comprehensive collection of ‘‘molecular
concepts’’ representing > 2500 cancer-related gene ex-
pression signatures from Oncomine and manual cura-
tion of the literature, drug treatment signatures from the
Connectivity Map, target gene sets from genome-scale
regulatory motif analyses, and reference gene sets from
several gene and protein annotation databases. We
computed pairwise association analysis on all 13,364
molecular concepts and identified > 290,000 significant
associations, generating hypotheses that link cancer
types and subtypes, pathways, mechanisms, and drugs.
To navigate a network of associations, we developed
an analysis platform, the Molecular Concepts Map. We
demonstrate the utility of the approach by highlighting
molecular concepts analyses of Myc pathway activation,
breast cancer relapse, and retinoic acid treatment.
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Introduction
Genome-scale molecular analyses are being widely em-
ployed to study human biology and disease. For exam-
ple, hundreds of studies have examined gene expression
profiles of human cancers identifying molecular subtypes
associated with cancer progression, response to therapy,
and patient outcome [1–6]. The Oncomine database rep-
resents a concerted effort to integrate and analyze such
data, now including 270 independent studies comprising
nearly 20,000 microarray experiments. In addition to the
profiling of tumors and other disease specimens, a number
of studies have profiled a wide variety of biologic perturbations
in cell lines, including genetic modifications and drug treat-
ments. For example, a series of experiments characterized the
transient activation of various known oncogenes in mammary
epithelial cells and defined gene expression signatures capable
of predicting pathway activation in human tumors and sensi-
tivity to specific inhibitors in cell lines [7]. Another genome scale
analysis, the Connectivity Map, examined hundreds of com-
pound treatment gene expression profiles and showed that
such profiles could be used in a screen to identify compounds
capable of reversing a gene expression program active in dis-
ease [8]. Although gene expression studies are the predomi-
nant type of genome-scale molecular analyses to date, other
high-throughput experimental modalities include proteomic
profiling, transcription factor binding analysis, epigenetic pro-
filing, and sequence-based analyses. In addition, several sys-
tematic annotation efforts have provided a variety of valuable
genome-scale characterizations.
A limitation of genome scale analyses to date is that they are
often carried out in isolation, with the end product being a list of
genes or proteins and a functional commentary. It may very well
be that disparate analyses have identified common genes, pro-
teins, and pathways, suggesting unknown and perhaps un-
expected functional relationships. For example, one study may
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activate a transcription factor in cell lines and measure target
genes; another study may investigate a protein complex using
mass spectrometry; a third study may characterize genes
activated in a subtype of disease; and a fourth study may
identify genes deregulated by drug treatment. One can imag-
ine a scenario in which all four studies were unknowingly
biologically related, leading to the identification of overlapping
genes and proteins. However, by today’s publishing conven-
tion, it would be unlikely that the respective investigators or the
research community at large would make these associations.
With an integrative analysis platform coupled with a dedicated
curation effort, one may be able to make these important
functional connections and thus derive unexpected biologic
insight in this hypothetical scenario, identifying relationships
among a transcriptional program, a protein complex, a dis-
ease subpopulation, and drug treatment.
Along these lines, several tools are available to com-
pare a query gene list to a reference set of gene lists. For
example, Gene Set Enrichment Analysis allows one to com-
pare a query signature to a variety of gene sets based
on pathways, Gene Ontology terms, regulatory motifs, chro-
mosomal regions, and perturbation experiments [9]. Another
tool, L2L, compares a query gene list with differential ex-
pression gene lists published in the literature [10]. In addition,
the Connectivity Map permits the analysis of a query signa-
ture against a database of drug treatment signatures [8].
These approaches have been applied successfully and dem-
onstrate the utility of gene sets as a common language to
compare heterogeneous biologic concepts.
Here, we have applied and extended the notion of com-
paring diverse biologic concepts represented by molecular
signatures (i.e., sets, lists, and so on). We integrated a
comprehensive collection of signatures relevant to cancer
research and performed all-versus-all association analyses.
Unlike approaches that analyze a single target signature
across a set of reference signatures, our approach computes
a network of associations across all available signatures
representing hundreds of cancer types and subtypes, bio-
logic perturbations, drug treatments, manually annotated
pathways and protein interaction networks, predicted regu-
latory networks, gene ontologies, and protein families. This
association analysis builds on Oncomine, the Connectivity
Map, and the work of profiling and annotation communities
to systematically connect cancer types and subtypes, path-
ways, mechanisms, and drugs. We designated this project
as the Molecular Concepts Map (MCM) because the focus
of the project is on biologic concepts represented by molec-
ular signatures.
Materials and Methods
Molecular Concepts Data Collection
Sets of biologically related genes were collected or de-
rived from 503 microarray studies and 12 external data-
bases. All identifiers were mapped to Entrez Gene IDs for
analysis. For each molecular concept, a null set was defined
as the set of all genesmeasured or considered in defining the
concept. For example, null sets for microarray-based con-
cepts were defined as all genes measured on a microarray
platform, whereas null sets for Gene Ontology–based con-
cepts were defined as all genes with at least one Gene
Ontology annotation.
Oncomine Data
Cancer signatures were derived from differential expres-
sion analyses that compared two logical groupings of nor-
mal or malignant human tissue or cell lines as defined by
the Oncomine Cancer Microarray Database (http://www.
oncomine.org) [11]. In total, data fromf 18,000 microarrays
from 270 independent studies were used in this analysis.
From Oncomine, we downloaded gene lists rank-ordered by
P value (Student’s t test) from 1192 differential expression
analyses. We defined gene signatures as the top 1%, 5%,
and 10% of overexpressed or underexpressed genes from
each analysis. We selected multiple cutoffs to allow for
variability in the optimal association cutoff. Only the most
significant of the three cutoffs is reported.
Connectivity Map Data
Drug overexpression and underexpression signatures
were derived from the Connectivity Map dataset [8]. The
dataset was normalized as described [11], except that nor-
malized expression values of < 0.5 were set to 0.5. Each
compound treatment experiment was compared to the ap-
propriate control experiment(s) based on the assigned batch
number. When multiple replicates were available, expres-
sion values were averaged. Genes that did not have a nor-
malized expression value of > 0.0 in either treatment or
control experiments were further filtered. Genes were then
rank-ordered by overexpression and underexpression in
treatment versus control, and the top 1% and 5% over-
expression and underexpression genes were assigned to
molecular concepts.
Additional Data Sources
Chromosome arm and cytoband mappings were down-
loaded from the National Center for Biotechnology Information
(NCBI) map viewer (http://www.ncbi.nlm.nih.gov/mapview/).
Biologic processes, molecular functions, and cellular com-
ponent annotations from the Gene Ontology Consortium
(http://www.geneontology.org/) [12] were downloaded from
Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db=gene). Metabolic pathways were downloaded from
the Kyoto Encyclopedia of Genes and Genomes (KEGG;
http://www.genome.jp/kegg/) [13]. Biocarta signaling pathways
were downloaded from the Biocarta web site (http://www.
biocarta.com/). Protein domains and family assignments were
downloaded from InterPro (http://www.ebi.ac.uk/interpro/) [14].
Protein–protein interaction sets were downloaded from the
Human Protein Reference Database (HPRD; http://www.
hprd.org/) [15]. Literature-defined concepts were collected
from 207 peer-reviewed publications that applied Affymetrix
(Santa Clara, CA) arrays to study the transcriptional effects of
an experimental perturbation such as drug treatment or can-
didate gene activation.
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Transcription Regulation Data
TRANSFAC transcription factor motifs were defined by
scanning all human gene promoter sequences for the pres-
ence of 361 experimentally defined transcription factor binding
sites [16]. One-kilobase promoter sequences from 20,647
RefSeqs were downloaded from the UCSC genome browser
(http://hgdownload.cse.ucsc.edu/goldenPath/hg17/bigZips/) in
August 2004. Sequenceswere sequentially submitted tomatch
a component of the TRANSFAC Professional Suite that scans
a sequence for the presence of transcription factor binding
sites, as determined by a database of position weight ma-
trices. A hit list was filtered to contain only the top 2000 hits per
matrix sorted by the matrix similarity score. Conserved pro-
moter motifs and conserved 3V untranslated region motifs were
defined by a comparative genomics analysis that identified
conserved motifs across four mammalian organisms [17].
Predicted microRNA target genes were downloaded from
picTar (http://pictar.bio.nyu.edu/), a resource that applies a
comparative genomics algorithm to identify putative miRNA
target gene sets [18].
Data Analysis
To carry out molecular concepts analysis, each pair of
molecular concepts was tested for association using Fisher’s
exact test. Results were stored if a given test had an odds
ratio of >1.25 and P < .01. P < 1e 100 was set to 1e 100.
All concept associations presented in the manuscript and
supplementary materials represent a subset of statistically
significant associations (P < 1e  6). A complete set of
significant concept associations is available from the MCM
(http://www.oncomine.org).
Results and Discussion
Data Collection and Primary Analysis
We defined a ‘‘molecular concept’’ as any biologic con-
cept (e.g., disease, drug treatment, pathway, regulatory
mechanism, and so on) represented by a molecular signa-
ture (i.e., a collection of genes or proteins). For example,
Gene Ontology ascribes 241 genes to the apoptosis pro-
cess; InterPro names 16 proteins to the chemokine receptor
family; a comparative genomics study identified 1188 genes
with conserved promoter motifs corresponding to Myc bind-
ing sites; and an Oncomine analysis identified 410 genes
overexpressed in BRCA1 mutant ovarian cancer.
Here we attempted to collect all molecular concepts in the
biomedical knowledge space with relevance for cancer re-
search. We began by deriving gene signatures fromOncomine
(http://www.oncomine.org) [19], a cancer gene expression
database that includes data and differential expression analy-
ses from 270 independent profiling studies, comprising nearly
20,000 microarray experiments that profile normal and malig-
nant human tissue and cell lines. We derived gene expression
signatures from > 1000 differential expression analyses as
top-ranking overexpressed and underexpressed genes using
three percentile cutoffs (1%, 5%, and 10%). Gene signatures
were defined for normal tissue types, cancer types relative to
normal tissue, and cancer subtypes based on a variety of
clinical, pathological, and molecular attributes, such as muta-
tion status, treatment response, and patient outcome, among
others. In addition, gene signatures were computed for cell line
analyses based on factors such as drug sensitivity and path-
way activation.
To supplement Oncomine with additional gene expression–
based molecular concepts, we initiated a manual curation ef-
fort of published gene signatures related to human biology.
This effort amassed an additional 465 concepts, including sig-
natures of various cellular processes, biologic perturbations,
and drug treatments. We also included signatures of drug
response from the Connectivity Map [8] comprising 379 com-
pound treatment experiments spanning 184 unique com-
pounds, many of which are drugs approved by the Food and
Drug Administration. To complement this dataset dominated
by gene expression data, we included gene sets derived
from several reference databases compiling molecular con-
cepts based on chromosomal locations, protein domains and
families [14], molecular functions, cellular localizations, bio-
logic processes [12], signaling and metabolic pathways [13],
protein–protein interaction networks [15], and protein com-
plexes [20]. In addition, we collected data on transcriptional
regulation in the form of putative transcription factor target
gene sets derived by scanning human promoters for known
transcription factor motifs [21] and by comparative genomics
analyses that identified conserved promoter and 3V UTR ele-
ments [17,18], many of which correspond to known transcrip-
tion factor and miRNA binding sites, respectively. In total,
13,364 molecular concepts from 12 databases and 503 micro-
array studieswere collected and analyzed. Table 1 summarizes
Table 1. Molecular Concept Types.
Class Source Type Concepts
Annotation Gene Ontology Biologic process 855
Cellular component 249
Molecular function 818
InterPro Protein family 2072
Gene expression Oncomine Cancer signatures* 2382
Literature Perturbation signatures 485
Connectivity Map Drug signatures* 758
Regulatory TRANSFAC Promoter binding site sets 361
picTar miRNA target sets 168
Broad Conserved promoter motif 174
Conserved UTR motif 72
Cytogenetic NCBI Chromosome arm 47
Chromosome subregion 294
Pathways/
interactions
Biocarta Signaling pathways 260
KEGG Metabolic pathways 160
HPRD Ptn–Ptn interaction sets 4144
PINdb Nuclear protein complex 65
Five classes of molecular concepts were compiled from 13 sources. Onco-
mine and literature concepts were derived by integrating data from many
independent sources.
PINdb = Proteins Interacting in the Nucleus Database.
*The number of concepts reported includes one overexpression signature
and one underexpression signature from each Oncomine and Connectivity
Map profile. Concepts were generated from three overexpression Oncomine
signatures and three underexpression Oncomine signatures (top 1%, 5%,
and 10%), and from two overexpression and underexpression Connectivity
Map signatures (top 1% and 5%).
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the data collected or derived of each type, and Figure 1 depicts
the integration and analysis of such data in the MCM.
Molecular concepts were stored in a relational schema
that stratifies concepts by concept type and associates
concepts with Entrez Gene identifiers. In addition, for statis-
tical analysis, each concept was associated with a ‘‘null set,’’
which represents the full set of genes from which the con-
cept genes were defined. For each pair of concepts (n =
Figure 1. The MCM project. (A) Molecular concepts or biologically related gene sets were collected, standardized, and stored in the MCM database. Molecular
concepts were derived from 503 independent microarray studies comprising > 20,000 microarray experiments, 3 promoter scanning and comparative genomics
regulatory motif analyses, and 12 gene and protein annotation resources (Table 1). Molecular concepts were standardized to Entrez Gene identifiers. Each pair of
molecular concepts was compared and assessed for significant association with Fisher’s exact test. Pairs of concepts that exhibited statistically significant overlap
(P < 1e  6) were considered ‘‘linked.’’ A database-driven web application (http://www.oncomine.org) was developed to analyze and visualize molecular concepts
and concept links. The web application also serves as a portal for users to upload and analyze new concepts. (B) An overview of concept types represented in the
analysis. Table 1 provides exact concept counts. (C) Pairwise association analysis of all molecular concepts identified 322,656 pairs of significantly linked
concepts. The area of each circle is proportional to the number of significant associations between pairs of concept types.
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89,291,566), we counted the number of genes present in
both concepts and assessed the significance of overlap with
Fisher’s exact test, which is simple yet highly scalable. We
stored all significant (P < .01) associations but only con-
sidered highly significant (P < 1e  6) associations for the
analyses presented here. At this conservative threshold,
we found 292,139 concept links where, by chance, we would
only expect to find 89 links. As depicted in Figure 1C, sig-
nificant concept links were observed between nearly all
pairs of concept types, although the majority of significant
concept links were among pairs of Oncomine signatures
and pairs of Connectivity Map drug signatures. This is not
surprising because both datasets are known to contain
large sets of highly related signatures. To navigate the net-
work of concept associations, we developed the MCM web
application (http://www.oncomine.org). Users can search
concepts in the database by keyword or MCM ID, query
significant concept links, and visualize networks of concept
relationships. In addition, new concepts can be uploaded for
rapid analysis against the MCM database.
To demonstrate the utility of the MCM approach and a
cross section of results, we undertook a series of cases
studies, beginning with different types of molecular sig-
natures with relevance to cancer research and exploring
networks of concept links identified by our analysis. The
purposes of case studies were to illustrate the breadth of
results generated by MCM analysis, to demonstrate the
usefulness of the analysis by highlighting known or expected
results that were obtained objectively, and to suggest new
hypotheses relating cancer types and subtypes, pathways,
mechanisms, and drugs. Detailed results from the case
studies, including MCM IDs, odds ratios, and P values, are
provided in supplementary materials. All associations pre-
sented were within the P value threshold of 1e  6.
Oncogenic Pathway Signatures
The strategy of using genomic signatures as a surrogate
for oncogenic pathway activity has been previously demon-
strated by Bild et al. [7]. Here we sought to apply molecular
concepts analysis to extend the analysis of oncogenic path-
ways to all cancer types and subtypes represented in Onco-
mine. In addition, we sought to explore the processes and
networks deregulated by specific pathways and to inves-
tigate small molecules capable of affecting pathway acti-
vation. Although several signatures of oncogenic pathway
activation were analyzed in the MCM, including Ras, E2F,
b-catenin, Src, p53, and NF-nB, among others, we selected
the Myc pathway to illustrate the approach and to gain in-
sights into Myc signaling in cancer.
Myc is an oncogenic transcription factor that is capable of
regulating a variety of cellular processes, deregulated in a
wide range of human cancers, and often associated with ag-
gressive poorly differentiated tumors [22]. We began our
analysis with a signature of 940 genes (top 5%) activated by
c-Myc when transiently overexpressed in human mammary
epithelial cells [7]. We first sought to validate the signature
by examining associations with other molecular concepts
related to Myc. Not surprisingly, the Myc signature shared
significant overlap with an independent Myc signature gen-
erated in MCF-10 breast cancer cells [23] and an Myc sig-
nature measured in B cells [24], confirming that a common
Myc molecular program is detectable across independent
cell types. We also observed a significant overlap between
the Myc signature and genes with putative Myc binding sites
in their promoters, confirming that the signature consists, at
least in part, of direct Myc target genes. Of note, no other
molecular concepts of transcription factor putative target
genes scored higher.
Confident that the Myc signature is valid, we sought to
discover or validate cancer types and subtypes in which the
Myc program is most significantly activated. We selected 25
of the top-scoring molecular concepts [odds ratio (OR) > 2;
P < 1e  8] for further analysis and discussion (Table W1).
Figure 2A displays a concept map seeded with the Myc
signature and selected linked concepts. The most significantly
linked Oncomine signature, considering > 2000 signatures,
was a signature for IgG–Myc mutation lymphoma [25] (OR =
7; P < 1e  100) in which Myc is the known oncogenic
mutation. It is noteworthy that an Myc signature generated
artificially in human mammary epithelial cells can differentiate
in vivo lymphomas by Myc status (Figure 1B). The MCM also
included a signature of N-Myc amplification-positive neuro-
blastoma [26], which was significantly related to the queryMyc
signature as well (OR = 4; P < 3.7e  9). In addition to these
malignancies with obvious Myc involvement, the MCM iden-
tified several additional cancer types with coordinate activa-
tion of the Myc program, including metastatic prostate cancer
(versus localized), grade III breast cancer (versus grades I and
II), colon adenocarcinoma (versus normal colon), FLT3 inter-
nal tandem duplication acute myeloid leukemia (AML; versus
FLT3 wild type), acute lymphoblastic leukemia with mixed
lineage leukemia (MLL) AF4 translocation (versus other
aberrations), chronic myeloid leukemia undergoing blast
crisis (versus chronic phase), and plasma cell leukemia
(versus other B-cell malignancies), among others (Figure 2,
Table W1). As depicted in Figure 2A, several of these
associations were validated by signatures from independent
datasets. For example, four independent signatures of grade
III breast cancer were highly linked to Myc activation, as well
as to one another, confirming the importance of the Myc
pathway in this subset of breast tumors. This observation is
consistent with previous reports that Myc activation through
either gene amplification or overexpression of an Myc-
stabilizing protein is highly associated with grade III breast
cancer relative to grade I and grade II diseases [27]. Similarly,
Myc has been previously linked to prostate cancer progres-
sion and metastatic disease [28], consistent with our observa-
tion of Myc pathway activation in several independent
metastatic prostate cancer signatures (Figure 2, A and B).
Lastly, our observed link between Myc activation and blast
crisis in chronic myeloid leukemia is also consistent with
previous reports [29]. It is important to note that although
previous work has suggested Myc involvement in these ma-
lignancies, our analysis provides additional evidence that the
Myc program is activated, as evidenced by the coordinate
overexpression of target genes. In addition to validating cancer
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types and subtypes with Myc pathway activation, our analysis
generated several new hypotheses linking Myc activity to
specific disease subpopulations, such as myeloid leukemias,
with FLT3 mutations and lymphoblastic leukemias with MLL-
AF4 translocations (Table W1).
Next, we sought to identify small molecules capable of
reversing the Myc expression program in vitro, with the goal
of suggesting treatment strategies for tumors with Myc
pathway activation. Thus, we focused our attention on drug
signatures from the Connectivity Map resource. We identi-
fied four highly significant links between drug treatments and
Myc pathway activation (OR > 3; P < 1e  15). All four
consisted of genes repressed by treatment with one of two
PI3K inhibitors (LY-294002 and wortmannin) in MCF-7 breast
cancer cells or HL-60 leukemia cells, suggesting that block-
ing PI3K signaling represses the Myc program more so than
any other compound represented in the Connectivity Map
(Figure 2, A and C). We considered that the repression of the
Myc program may be mediated by the downregulation of
c-Myc itself, but on the contrary, we found that Myc expres-
sion was not affected by PI3K inhibition in these experi-
ments. Thus, we hypothesized that other signaling events
downstream of PI3K may be necessary for the activation of
the Myc transcriptional program. Supporting this hypothesis,
previous work has shown that AKT-mediated phosphoryla-
tion of FOXO proteins is required for Myc induction of pro-
liferation and transformation and that PI3K inhibition with
LY-294002 leads to repression of Myc target genes [30].
MCM analysis shows that PI3K inhibition represses a large
fraction of the Myc transcriptional program, further suggest-
ing PI3K inhibition as a strategy for treating Myc-driven
malignancies. Notably, the associations hold up across
cellular backgrounds and independent PI3K inhibitors.
Similar results have been computed for additional cancer-
related pathways, including Ras, Src, b-catenin, E2F,
NF-nB, and p53, and are available online (http://www.
molecularconcepts.org). For example, similar to the results
for the Myc activation signature, the Ras activation signature
was linked to a number of cancer types and subtypes, several
of which have known Ras pathway involvement, including
N-Ras mutant melanoma (versus B-Raf and wild type),
K-Ras mutant lung adenocarcinoma (versus wild type), and
K-Ras mutant AML (versus wild type) (Table W2). Additional
links suggest that the Ras pathway is activated in cell lines
resistant to several common cytotoxic agents, is relatively
more active in specific solid tumor types (such as bladder,
colon, and cervical tumors), and is less active in tumor types
such as prostate and breast (Table W2).
Disease Signatures: Relapse-Positive Breast Cancer
Next, we investigated the ability of the MCM to decon-
struct complex disease signatures consisting of hundreds of
genes differentially expressed in a given disease state rela-
tive to normal tissue or other disease states. To illustrate
this analysis, we considered gene expression signatures of
relapse in estrogen receptor–positive (ER+) and estrogen
receptor–negative (ER) breast cancer, as metastatic re-
lapse following surgery is the principal cause of mortality. We
considered ER+ and ER tumors as separate disease enti-
ties and sought to compare and contrast molecular concepts
associated with relapse in each. Both signatures consisted of
the top 5% of genes overexpressed in tumors that relapsed
within 5 years of surgery relative to tumors that did not
relapse [6]. Previous studies have examined genes associ-
ated with breast cancer relapse identifying associations with
fibroblast serum response [31] and cell cycle program [32].
We anticipated that our analysis should recapitulate these
results and identify additional molecular concepts related to
relapse signatures.
First, we examinedmolecular concepts associated with the
ER+ relapse signature. Several hundred concepts were highly
linked, of which a subset is presented here (Table W3). Con-
firming the validity of the signature, we observed that some of
the most significant associations were with breast cancer
relapse signatures generated from independent datasets. In
addition, the ER+ relapse signature was highly associated
with several additional high-grade/poorly differentiated can-
cer signatures, suggesting that the ER+ relapse signature is
not unique to breast cancer. With respect to pathway signa-
tures, the ER+ relapse signature showed evidence of E2F and
Myc pathway activation, consistent with previous work [23].
We also observed an enrichment of E2F promoter binding
sites in the ER+ relapse signature, further confirming the acti-
vation of this pathway. Similar to previous reports, we ob-
served an association with fibroblast serum response and
cell cycle signatures [33]. In addition, several ontological con-
cepts showed strong associations, including mitosis, DNA
repair, and chromosome organization, as well as the his-
tone core and ATPase protein domain concepts—all con-
sistent with increased proliferation in ER+ relapse breast
tumors. Interestingly, several specific chromosomal cyto-
bands showed significant associations with the ER+ relapse
signature, including 17q25, 8q24, and 20q13, signifying chro-
mosomal aberrations that likely contribute to the expres-
sion of the relapse signature. In fact, all three regions have
been documented to be amplified in a subset of breast tu-
mors [34]. Lastly, a number of biologic perturbation concepts
Figure 2. Molecular concepts analysis of the Myc pathway activation signature, consisting of the top 5% of genes most overexpressed in Myc transfection in human
mammary epithelial cells [24]. (A) A molecular concepts map of the Myc signature (red node) and selected significantly linked concepts. Each node represents a
molecular concept or a set of biologically related genes. The size of the node is proportional to the number of genes in the concept. The color of the concept indicates
concept type (see legend). Each edge signifies a statistically significant association (P < 1e  6). The drug signatures consist of genes downregulated by drug
treatment in the specified cell line. HMECs = human mammary epithelial cells. Concept details are provided in Table W1. (B) Representative heatmaps depicting Myc
pathway activation in Ig-Myc–positive lymphoma, metastatic prostate cancer, colorectal carcinoma, and grade III breast cancer. Each heatmap column is an individual
tumor. Each row is a gene from the Myc activation signature. Red and blue indicate relative overexpression and underexpression, respectively. Ig-Myc = Myc
translocation involving immunoglobulin locus; DLBCL = diffuse large B-cell lymphoma; B-UC = B-cell lymphoma unclassified; BL = Burkitt’s lymphoma; Met =
metastatic prostate cancer; BCa = breast carcinoma. (C) Representative heatmaps depicting Myc pathway repression by LY-294002 and wortmannin treatments.
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showed strong associations with the ER+ relapse signature,
including hypoxia, radiation toxicity, treatment with a meth-
ylase inhibitor, or treatment with selective ER modulators.
Finally, a number of Connectivity Map signatures linked small
molecules with the ER+ relapse signature, identifying com-
pounds that repress the expression of the relapse signature.
The most significant compound treatment, resveratrol, is
known to inhibit the cell cycle [35], consistent with our obser-
vation that the cell cycle program is activated in the ER+
relapse signature and is downregulated by resveratrol. Other
agents scoring highly include geldamycin (a heat shock
protein inhibitor) and derivatives, as well as PI3K inhibitors,
consistent with our previous observation linking Myc pathway
activation and PI3K inhibition. Although preliminary, these
results suggest that resveratrol and PI3K inhibitors, perhaps
in addition to cytotoxic agents, should be considered as
adjuvant therapy for ER+ breast cancers expressing the
relapse signature. Figure 3A depicts a molecular concepts
map seeded with the ER+ relapse signature, demonstrating
the interrelatedness of identified molecular concepts. Interest-
ingly, the Myc and E2F pathway activation concepts were not
linked to one another and were linked to separate molecular
concepts, suggesting that different components of the relapse
signature are controlled by different oncogenic pathways.
Next, we investigated the ER relapse signature. It should
be noted that although the ER+ relapse signature consisted
of genes significantly overexpressed (Q < 0.05) in relapse
tumors, the genes in the ER relapse signature did not reach
statistical significance (Q < 0.05), even though the collection
of genes assigned to the ER relapse signature did have
a number of significant associations in molecular concepts
analysis. To our surprise, none of the concepts associated
with the ER+ relapse signature was also associated with the
ER relapse signature, suggesting that distinct pathways
mediate cancer progression in ER+ and ER breast cancer
(Table W4). Notably, the ER relapse signature was signifi-
cantly associated with independent Her2/neu+ breast cancer
signatures, suggesting that the Her2/neu pathway or related
pathways may drive progression in ER tumors. Consistent
with this observation, Her2/neu was found to be significantly
overexpressed in ER relapse tumors, although not in all
ER relapse tumors, suggesting alternative pathways that
activate a Her2/neu–like program. Unlike the ER+ relapse
signature that showed evidence for the activation of the Myc
and E2F pathways, the ER relapse signature was associ-
ated most significantly with the c-Src pathway, in addition to
the Ras pathway. In addition, of note, the ER relapse sig-
nature was associated with overexpression of genes local-
ized to chromosome Xp11, but not to cytobands detected in
the ER+ relapse signature. Finally, with respect to drugs that
may be able to reverse the ER relapse signature, only one
drug signature was significantly associated—valproic acid, a
histone deacetylase inhibitor. We observed that a significant
fraction of genes overexpressed in the ER relapse signa-
ture were repressed in PC3 cells treated with valproic acid,
suggesting a potential therapeutic strategy for ER tumors
expressing the relapse signature. In summary, molecular
concepts analysis demonstrated that breast cancer progres-
sion is mediated by distinct pathways and mechanisms in
ER+ and ER tumors and, importantly, suggested hypothe-
ses regarding therapeutic strategies that may be best suited
to reverse the respective relapse signatures.
In a parallel analysis on prostate cancer progression
[36], we applied molecular concepts analysis to inter-
pret progression signatures generated from laser capture–
microdissected prostate cells. As described, we obtained
gene expression profiles spanning the complete spectrum
of prostate cancer progression, including benign prostatic
epithelial and stromal cells, prostatic intraepithelial neoplasia
(PIN), low-grade (Gleason pattern 3) prostate cancer, high-
grade (Gleason pattern 4) prostate cancer, and metastatic
disease. Molecular concepts analysis of transition states led
to a number of insights. For example, PIN signature was
linked to protein biosynthesis and ETS promoter motifs,
whereas the transition from low-grade to high-grade pros-
tate cancer was linked to downregulated androgen sigaling,
and the transition to metastatic disease was linked to cell
cycle activation and overexpression of genes on chromo-
some 8q. This analysis further demonstrates the ability of a
diverse collection of molecular concepts to elucidate biologic
mechanisms underlying complex disease signatures.
Drug Signatures
Next, we explored the notion of matching gene signatures
to identify drugs that are capable of reversing a gene ex-
pression program and thus treating a particular condition
[7,37]. The approach proposed by Lamb et al. [8] begins with
a disease signature and compares it against a reference
database of drug signatures to identify drugs that may be
able to reverse the disease signature. Here, we investigate
the converse experiment, that is, beginning with a drug
signature (e.g., genes repressed by drug treatment) and
searching for disease types or subtypes that show coordi-
nate activation of the signature, suggesting novel (or ex-
pected) indications for the drug.
To test this approach, we considered a drug signature
consisting of genes repressed in acute promyelocytic leuke-
mia (APL) cells treated with retinoic acid in vitro [38]. Because
retinoic acid is a potent differentiating agent and is uniquely
effective in treating APL due to activating retinoic acid receptor
(RAR) translocation, we hypothesized that genes repressed
by retinoic acid in vitro should be overexpressed in APL cases
but not in other AML subtypes that do not have RAR trans-
location. As anticipated, several independent APL signa-
tures, derived from analyses of M3 AML clinical specimens
(i.e., APL) compared to other AML subtypes, showed a
highly significant association with the retinoic acid signature
(Table W5)—in fact stronger than any other Oncomine can-
cer signatures. This suggests that had retinoic acid not been
known to be an effective treatment for APL, our analysis would
have correctly prioritized APL as the optimal disease popula-
tion for retinoic acid treatment, granted the drug treatment
experiment was performed in the appropriate cellular con-
text. Interestingly, the retinoic acid repression signature also
showed a strong association with independent MLL signa-
tures and a renal cell carcinoma signature, among others
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Figure 3. Molecular concepts analysis of an ER+ breast cancer relapse signature (MCM: 122567) consisting of the top 5% of genes most overexpressed in ER+
tumors from patients who relapsed within 5 years relative to those who did not. (A) A molecular concepts map of the ER+ relapse signature (yellow node) and
selected significantly linked concepts. Each node represents a molecular concept or a set of biologically related genes. The size of the node is proportional to the
number of genes in the concept. The color of the concept indicates concept type (see legend). Each edge signifies a statistically significant association (P < 1e 
6). The drug signatures consist of genes downregulated by drug treatment in the specified cell line. HMECs = human mammary epithelial cells. Concept details are
provided in Table W2. (B) Representative heatmaps depicting the expression of cell cycle, serum response, and 17q25 concepts in the dataset from which the ER+
relapse signature was derived. Each heatmap column is an individual ER+ breast tumor. Each row is a gene from the ER+ relapse signature and denoted concepts.
Red and blue indicate relative overexpression and underexpression, respectively.
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(Table W5). These associations suggest potential additional
indications for retinoic acid, both of which are supported by
preliminary experimental evidence [39,40]. In addition to these
cancer signature associations, the repressed-by-retinoic-acid
signature was significantly linked to five drug treatment sig-
natures from the Connectivity Map, including two signatures
of genes repressed by tretinoin (i.e., retinoic acid) in MCF-7
and HL-60 cells. These associations demonstrate cell type–
independent gene expression changes caused by retinoic
acid inhibition. As displayed in the molecular concepts map
centered on the APL retinoic acid repression signature
(Figure 4), the MCF-7 tretinoin signature is also linked to
two of three APL signatures from clinical specimens, demon-
strating an objective association of a drug signature with a
disease subpopulation in which treatment is known to be
effective, irrespective of cell type. This analysis further sup-
ports the notion of mapping drug signatures with disease
signatures and suggests that such an analysis can begin with
a drug signature to scan a database of disease signatures to
identify optimal disease populations. Analogous associations
have been computed and are available online for a number of
other drug treatment experiments collected from the literature
Figure 4. Molecular concepts analysis of a retinoic acid signature, consisting of 454 genes repressed in APL cells treated with retinoic acid. (A) A molecular
concepts map of the retinoic acid signature (yellow node) and selected significantly linked concepts. Each node represents a molecular concept or a set of
biologically related genes. The size of the node is proportional to the number of genes in the concept. The color of the concept indicates concept type (see legend).
Each edge signifies a statistically significant association (P < 1e  6). The drug signatures consist of genes downregulated by drug treatment in the specified cell
line. HMECs = human mammary epithelial cells; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia. Concept details are provided in Table W4.
(B) A heatmap depicting genes from the retinoic acid signature in an AML dataset from which an M3 (APL) signature was derived. Each heatmap column is an
individual AML specimen. Each row is a gene from the retinoic acid signature. Red and blue indicate relative overexpression and underexpression, respectively.
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and from the Connectivity Map resource, suggesting cancer
types and subtypes that might be responsive to drug treat-
ment. Table W6 lists a sample of highly significant associa-
tions between drugs and cancer types.
In summary, we have assembled a collection of gene sig-
natures representing cancer types and subtypes, pathways,
mechanisms, and drugs, and we have performed a large-
scale association analysis comparing each pair of signa-
tures. In addition, we have developed the MCM to store and
navigate the signatures and their associations. Although this
effort represents the beginning of an ambitious initiative to
assimilate and integrate all molecular concepts into the bio-
logic knowledge space, the results presented here demon-
strate the ability of the approach to objectively validate
hypotheses and to generate new hypotheses across diverse
datasets and databases. For example, Myc analysis, repre-
senting one cross section of the results, validated the Myc
signature against independent Myc signatures, confirmed
Myc pathway activation in tumor subtypes with known Myc
involvement, and suggested additional tumor types and
subtypes with Myc activation. In addition, the analysis iden-
tified a class of compounds capable of indirectly repressing
the Myc pathway in vitro, suggesting a therapeutic strategy
for treating Myc-driven tumors. Notably, all of these asso-
ciations were made from data deposited from the public
domain, made possible by a concerted data curation effort
coupled with a simple association analysis. Our analysis
platform is simple and highly extensible, and we anticipate
that it will serve as a powerful framework for integrating
disparate molecular concepts and for generating new hy-
potheses and biologic insight.
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Table W1.
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:142645 Human primary mammary epithelial cells
oncogene transfected—top 5% overexpressed
in c-Myc (10) vs control—GFP (10) (Bild)
940
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:8463322 Lymphoma Myc fusion—top 10% overexpressed
in IG-Myc (Hummel)
1240 1.20E-100 7.01
Oncomine gene expression signatures MCM:22212056 Acute lymphoblastic leukemia genetic features—
top 10% overexpressed in MLL-AF4 positive
(Kirschner-Schwabe)
1240 1.90E-74 5.46
Oncomine gene expression signatures MCM:22210396 Breast carcinoma grade—top 10% overexpressed
in 3 (Bittner)
1880 1.30E-64 4.23
Oncomine gene expression signatures MCM:8453592 Prostate type—top 10% overexpressed in metastatic
(Vanaja)
1720 3.50E-57 3.98
Oncomine gene expression signatures MCM:22210226 Breast carcinoma Elston grade—top 10%
overexpressed in 3 (Miller)
1240 7.90E-55 4.44
Oncomine gene expression signatures MCM:130778 Acute myeloid leukemia FLT3 internal tandem
duplication—top 10% overexpressed in
pos (Valk)
1240 6.20E-50 4.1892
Oncomine gene expression signatures MCM:8463582 Plasma cell dyscrasia type—top 10% overexpressed
in plasma cell leukemia (Mattioli)
1240 1.10E-48 4.12
Literature-defined concepts MCM:122567 Upregulated genes in human B cells upon Myc gene
expression
59 1.50E-39 43.7609
Oncomine gene expression signatures MCM:120992 Prostate type—top 10% overexpressed in lymph
node metastasis (Lapointe)
980 7.80E-39 3.7969
Connectivity map MCM:21639806 MCF cell treatment—top 5% underexpressed in 505,
MCF7 treated with wortmannin (0.00000001 M)
for 6 h (Lamb)
620 3.60E-38 4.84
Oncomine gene expression signatures MCM:125550 Breast ductal carcinoma grade—top 10%
overexpressed in III (Zhao)
1200 1.30E-36 3.3882
Conserved promoter motif MCM:118930 CLUSTER_2__V$MYC_Q2 1188 1.00E-35 3.7069
Oncomine gene expression signatures MCM:133658 Colon type—top 10% overexpressed in colon
adenocarcinoma (Notterman)
390 2.70E-31 6.422
Oncomine gene expression signatures MCM:8462882 Colon type—top 10% overexpressed in colorectal
carcinoma (Graudens)
600 3.60E-29 3.8
Oncomine gene expression signatures MCM:7221222 Chronic myelogenous leukemia phase—top
10% overexpressed in blast crisis (Radich)
1480 8.40E-27 2.8
Oncomine gene expression signatures MCM:125352 Acute lymphoblastic leukemia translocation—top 10%
overexpressed in MLL-AF4 (Tsutsumi)
719 1.60E-23 3.6825
Connectivity map MCM:21641086 Cell line batch—description—top 5% underexpressed
in 35, HL60 treated with LY-294002 (0.00001 M) for
6 h (Lamb)
620 1.30E-22 3.56
Oncomine gene expression signatures MCM:8467212 Breast carcinoma grade—top 10% overexpressed
in 3 (Sotiriou)
1240 3.00E-22 2.72
Oncomine gene expression signatures MCM:130915 Breast carcinoma grade—top 10% overexpressed
in 3 (van)
1500 8.40E-22 2.5572
Connectivity map MCM:21639506 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with wortmannin (0.000001 M)
for 6 h (Lamb)
620 5.50E-21 3.41
Oncomine gene expression signatures MCM:22212096 Prostate adenocarcinoma type—top 10%
overexpressed in metastasic prostate cancer
(Holzbeierlein)
470 3.80E-20 4
Connectivity map MCM:21639856 MCF cell treatment—top 5% underexpressed in 506,
MCF7 treated with LY-294002 (0.00001 M) for
6 h (Lamb)
620 2.20E-18 3.19
Oncomine gene expression signatures MCM:7638672 MCF10a cells MYC and CSN5 transfection—top 5%
overexpressed in MYC (Adler)
690 3.30E-14 2.68
Transfac TF matrix—1000 bp MCM:113189 N-Myc 1300 5.30E-10 1.9755
Transfac TF matrix—1000 bp MCM:115469 c-Myc:Max 775 2.60E-09 2.2204
Oncomine gene expression signatures MCM:8461802 Neuroblastoma MYCN status—top 5% overexpressed
in amplified (Ohira)
145 3.70E-09 3.99
The first section of Tables W1 to W5 denotes the query molecular concept. The second section lists selected molecular concepts that were significantly associated
with the query concept. P values were calculated from a Fisher’s exact test. The results can be recapitulated at www.molecularconcepts.org using the MCM IDs
provided in the table.
Table W2.
Concept type MCM ID Concept No. of Genes
Oncomine gene expression signatures MCM:142630 Human primary mammary epithelial cells oncogene
transfected—top 5% overexpressed in activated
H-Ras (Bild)
940
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:21463146 Brain type—top 10% overexpressed in glioblastoma
multiforme (Sun)
1880 7.00E-58 3.96
Oncomine gene expression signatures MCM:8463182 Cell line doxorubicin sensitivity—top 10%
overexpressed in resistant (Gyorffy)
1240 4.90E-46 3.86
Oncomine gene expression signatures MCM:11632232 Cancer type—top 10% overexpressed in cervix
squamous cell carcinoma (Bittner)
1880 6.80E-46 3.48
Oncomine gene expression signatures MCM:22230236 Bladder type—top 20% overexpressed in invasive
transitional cell carcinoma (Dyrskjot)
2480 7.20E-43 2.98
Oncomine gene expression signatures MCM:11632212 Cancer type—top 10% overexpressed in bladder
transitional cell carcinoma (Bittner)
1880 1.10E-42 3.35
Connectivity map MCM:21635286 MCF cell treatment—top 5% overexpressed in 502,
MCF7 treated with ionomycin (0.000002 M) for
6 h (Lamb)
620 1.00E-37 4.66
Connectivity map MCM:21635816 MCF cell treatment—top 5% overexpressed in 505,
MCF7 treated with celastrol (0.0000025 M) for
6 h (Lamb)
620 2.20E-36 4.56
Oncomine gene expression signatures MCM:22231726 Melanoma culture type—top 20% overexpressed
in cutaneous melanoma (Hoek)
2480 2.40E-36 2.78
Oncomine gene expression signatures MCM:126230 Renal clear cell carcinoma grade—top 10%
overexpressed in III (Lenburg)
1720 6.30E-36 3.0994
Oncomine gene expression signatures MCM:8449332 Lung carcinoma 3-yr survival—top 10% overexpressed
in dead (Bild)
1880 3.80E-34 2.99
Oncomine gene expression signatures MCM:3116782 Sarcoma type—top 10% overexpressed in
leiomyosarcoma (Henderson)
840 8.90E-34 3.79
Oncomine gene expression signatures MCM:11632242 Cancer type—top 10% overexpressed in colon
adenocarcinoma (Bittner)
1880 2.40E-31 2.87
Oncomine gene expression signatures MCM:11632582 Cancer type—top 10% underexpressed in breast
ductal carcinoma (Bittner)
1880 5.70E-30 2.82
Oncomine gene expression signatures MCM:123578 Breast carcinoma estrogen receptor status—top 10%
underexpressed in positive (Wang)
1240 1.90E-28 2.9877
Oncomine gene expression signatures MCM:22242696 Cervical carcinoma differentiation—top 20%
underexpressed in poor (Bachtiary)
3760 2.10E-28 2.29
Oncomine gene expression signatures MCM:11632792 Cancer type—top 10% underexpressed in prostate
adenocarcinoma (Bittner)
1880 9.40E-28 2.72
Connectivity map MCM:21636176 MCF cell treatment—top 5% overexpressed in 506,
MCF7 treated with thioridazine (0.00001 M) for
6 h (Lamb)
620 9.50E-25 3.63
Oncomine gene expression signatures MCM:11632452 Cancer type—top 10% overexpressed in rectal
adenocarcinoma (Bittner)
1880 2.30E-24 2.57
Oncomine gene expression signatures MCM:8463172 Cell line vinblastin sensitivity—top 10% overexpressed
in resistant (Gyorffy)
1240 1.50E-22 2.67
Connectivity map MCM:21635606 MCF cell treatment—top 5% overexpressed in 504,
MCF7 treated with pyrvinium (0.00000125 M) for
6 h (Lamb)
620 5.30E-22 3.41
Oncomine gene expression signatures MCM:22230016 Lung carcinoma histology—top 20% overexpressed
in adenocarcinoma (Bittner)
3760 6.00E-22 2.08
Oncomine gene expression signatures MCM:117773 Lung type—top 10% overexpressed in lung
adenocarcinoma (Bhattacharjee)
770 8.20E-22 3.1326
Oncomine gene expression signatures MCM:8463192 Cell line mitomycin C sensitivity—top 10%
overexpressed in resistant (Gyorffy)
1240 1.00E-21 2.63
Oncomine gene expression signatures MCM:22212126 Breast carcinoma estrogen receptor status—top 10%
underexpressed in positive (Yu)
880 1.30E-21 2.95
Connectivity map MCM:21635266 MCF cell treatment—top 5% overexpressed in 502,
MCF7 treated with geldanamycin (0.000001 M) for
6 h (Lamb)
620 1.80E-21 3.37
Connectivity map MCM:21635836 MCF cell treatment—top 5% overexpressed in 505,
MCF7 treated with clotrimazole (0.00005 M) for
6 h (Lamb)
620 1.80E-21 3.37
Oncomine gene expression signatures MCM:124888 Acute myeloid leukemia karyotype—top 10%
overexpressed in t(15;17) PML-RARa (Valk)
1240 4.70E-20 2.5426
Oncomine gene expression signatures MCM:131275 Brain survival—3 yr—top 10% overexpressed
in dead (Freije)
1720 8.30E-20 2.3744
Connectivity map MCM:21639806 MCF cell treatment—top 5% underexpressed in 505,
MCF7 treated with wortmannin (0.00000001 M) for
6 h (Lamb)
620 2.20E-19 3.19
Oncomine gene expression signatures MCM:22231766 Cutaneous melanoma mutation—top 20%
overexpressed in NRAS—Q61K (Hoek)
2480 1.10E-16 2.03
Table W3.
Concept type MCM ID Concept No. of Genes
Oncomine gene expression signatures MCM:117518 ER+ breast carcinoma disease free survival—5 yr—top
5% overexpressed in relapse (51) vs no disease (164)
(vandeVijver)
740
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:8467112 Breast carcinoma survival—5 yr—top 5% overexpressed
in dead (Pawitan)
860 1.10E-100 9.69
Oncomine gene expression signatures MCM:123728 Breast carcinoma estrogen receptor status—top 10%
underexpressed in 1 (vandeVijver)
1480 1.20E-100 6.8179
Oncomine gene expression signatures MCM:140004 ER+ breast carcinoma disease-free survival—5 yr—top
10% overexpressed in relapse (Wang)
1240 1.30E-84 6.6782
Oncomine gene expression signatures MCM:22210576 Breast carcinoma estrogen receptor status—top 10%
underexpressed in positive (Miller)
1240 1.40E-77 6.17
Oncomine gene expression signatures MCM:8619662 Breast carcinoma relapse—5 yr—top 10% overexpressed
in relapse (Sotiriou)
1240 5.40E-71 5.84
Oncomine gene expression signatures MCM:21463186 Oligodendroglioma grade—top 10% overexpressed in
grade 3 (Sun)
1880 3.40E-50 4.02
Literature-defined concepts MCM:100084 Differentially expressed genes in HeLa cells during the
cell cycle
712 1.30E-48 6.059
Oncomine gene expression signatures MCM:142117 Pancreas type—top 10% overexpressed in microdissected
pancreatic tumor epithelia (Grutzmann)
1710 1.30E-45 3.8736
Oncomine gene expression signatures MCM:8461672 Bladder carcinoma grade—top 5% overexpressed in
3 (Lindgren)
310 2.60E-45 9.18
Oncomine gene expression signatures MCM:123612 Prostate type—top 10% overexpressed in metastatic
prostate cancer (LaTulippe)
780 2.00E-44 5.645
Oncomine gene expression signatures MCM:8453582 Prostate adenocarcinoma grade—top 10% overexpressed
in metastatic (Vanaja)
1720 7.10E-43 3.73
Oncomine gene expression signatures MCM:8619892 Ovarian grade—top 5% overexpressed in IV (Lu) 850 3.60E-39 4.96
Oncomine gene expression signatures MCM:122199 Lung adenocarcinoma differentiation—top 10%
overexpressed in poor (Beer)
460 4.70E-37 6.5154
Oncomine gene expression signatures MCM:22231886 Breast carcinoma local recurrence—top 20%
overexpressed in yes (Kreike)
2060 2.90E-36 3.33
Oncomine gene expression signatures MCM:8437412 Astrocytoma WHO grade—top 10% overexpressed
in IV (Phillips)
1720 1.50E-32 3.22
Oncomine gene expression signatures MCM:22210366 Multiple myeloma survival—3 yr—top 10% overexpressed
in dead of disease (Zhan)
1880 4.20E-32 3.17
Oncomine gene expression signatures MCM:22212166 Cell line treatment—top 10% underexpressed in
5-fluorouracil (Troester)
1340 5.90E-30 3.28
Literature-defined concepts MCM:118117 Top-ranked UV-repressed genes in acute radiation
toxicity
718 1.80E-29 4.4134
Literature-defined concepts MCM:117714 Downregulated genes in response to hypoxia and
in response to HIF-1 expression
271 1.60E-28 6.8708
Literature-defined concepts MCM:118286 Downregulated genes in pancreatic cancer cells with
the methylase inhibitor 5-aza-2V-deoxycytidine
(5-aza-CdR)
116 6.00E-28 12.3013
Oncomine gene expression signatures MCM:22211856 Cell line treatment—top 5% underexpressed in
doxorubicin (Troester)
670 5.50E-27 4.06
Chromosome subregion MCM:110775 17q25 183 1.70E-23 10.2874
Literature-defined concepts MCM:118136 Downregulated genes by ICI, Ral, or TOT, but not
estradiol
50 5.40E-22 22.1846
Oncomine gene expression signatures MCM:142661 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in c-Myc (Bild)
1880 4.90E-21 2.565
Oncomine gene expression signatures MCM:142661 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in c-Myc (Bild)
1880 4.90E-21 2.565
Chromosome arm MCM:114061 8q 485 2.00E-20 4.9837
Chromosome subregion MCM:113366 8q24 155 6.00E-18 9.5343
Table W2. (continued)
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:121191 Lung adenocarcinoma K-ras mutation status—top 10%
overexpressed in positive (Beer)
460 1.60E-11 2.6895
Literature-defined concepts MCM:137462 Upregulated genes in RAS transformed ovarian surface
epithelial cell lines
20 6.70E-10 22.4204
Literature-defined concepts MCM:143314 Upregulated genes in K-ras expressing, immortalized
human pancreatic duct epithelial cells
57 3.30E-09 7.33
Oncomine gene expression signatures MCM:124895 Acute myeloid leukemia K-RAS mutation—top 10%
overexpressed in positive (Valk)
1240 1.60E-08 1.839
Table W3. (continued)
Concept type MCM ID Concept No. of Genes P Odds Ratio
GO biological process MCM:101773 Mitosis 85 5.00E-16 9.7288
GO biological process MCM:101476 DNA replication 90 1.80E-14 8.6168
Chromosome arm MCM:119913 17q 869 1.90E-14 3.0254
Connectivity map MCM:21642646 Cell line batch—description—top 5% underexpressed
in 95, MCF7 treated with resveratrol (0.00005 M) for
6 h (Lamb)
620 1.80E-13 2.9
GO biological process MCM:101579 Cytokinesis 110 9.40E-13 7.0205
Literature-defined concepts MCM:109034 Upregulated genes in fibroblasts in response to fibroblast
serum treatment
211 1.10E-12 4.7171
Chromosome arm MCM:120059 20q 379 1.90E-12 4.0973
GO biological process MCM:102757 Cell cycle 168 3.70E-12 5.1726
Connectivity map MCM:21639506 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with wortmannin (0.000001 M) for
6 h (Lamb)
620 7.70E-12 2.73
Oncomine gene expression signatures MCM:142659 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in E2F3 (Bild)
1880 2.90E-11 2.0042
Oncomine gene expression signatures MCM:142659 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in E2F3 (Bild)
1880 2.90E-11 2.0042
Chromosome arm MCM:119911 16q 422 3.00E-11 3.646
Connectivity map MCM:21639816 MCF cell treatment—top 5% underexpressed in 506,
MCF7 treated with 15-delta prostaglandin J2
(0.00001 M) for 6 h (Lamb)
620 3.50E-11 2.67
Connectivity map MCM:21639186 MCF cell treatment—top 5% underexpressed in 502,
MCF7 treated with resveratrol (0.00001 M) for
6 h (Lamb)
620 1.10E-10 2.59
GO molecular function MCM:106534 ATP binding 1146 2.40E-10 2.1859
Literature-defined concepts MCM:100904 Downregulated genes (time dependent) in prostate
cancer cells in response to resveratrol
501 3.80E-10 2.7577
Transfac TF matrix —1000 bp MCM:107871 E2F 1210 6.80E-10 2.119
Connectivity map MCM:21641356 Cell line batch—description—top 5% underexpressed
in 42, ssMCF7 treated with LY-294002 (0.00001 M)
for 6 h (Lamb)
620 2.00E-09 2.46
Connectivity map MCM:21639226 MCF cell treatment—top 5% underexpressed in 502,
MCF7 treated with wortmannin (0.000001 M) for
6 h (Lamb)
620 4.70E-09 2.42
Chromosome subregion MCM:116279 20q13 177 6.90E-09 5.1441
Connectivity map MCM:21639396 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with geldanamycin (0.000001 M) for
6 h (Lamb)
620 1.20E-08 2.38
Connectivity map MCM:21642566 Cell line batch—description—top 5% underexpressed
in 90, PC3 treated with resveratrol (0.00005 M) for
6 h (Lamb)
620 1.20E-08 2.35
Connectivity map MCM:21639236 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with 17-allylamino-geldanamycin
(0.000001 M) for 6 h (Lamb)
620 1.80E-07 2.22
Connectivity map MCM:21642626 Cell line batch—description—top 5% underexpressed
in 95, MCF7 treated with geldanamycin (0.000001 M)
for 6 h (Lamb)
620 2.60E-07 2.2
Conserved promoter motif MCM:119753 CLUSTER_5__V$NFY_Q6_01 1501 4.20E-07 1.819
InterPro MCM:115009 Histone core 71 4.40E-07 6.7457
Literature-defined concepts MCM:116121 Upregulated genes in HEK cell lines in response to
SV40 small tumor antigen (ST)
178 4.40E-07 3.67
Chromosome subregion MCM:112570 8q22 63 5.20E-07 7.3427
GO biological process MCM:101852 DNA repair 118 7.40E-07 4.3385
GO biological process MCM:101484 DNA replication initiation 19 7.80E-07 16.7008
GO biological process MCM:102290 Chromosome organization and biogenesis (sensu
Eukaryota)
67 8.10E-07 6.371
Table W4.
Concept type MCM ID Concept No. of Genes
Oncomine gene expression signatures MCM:135092 ER breast carcinoma disease-free survival—5 yr—top
5% overexpressed in relapse (28) vs no disease (32)
(vandeVijver)
740
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:125547 Breast ductal carcinoma HER2 status—top 10%
overexpressed in positive (Zhao)
1200 1.00E-13 2.4397
Oncomine gene expression signatures MCM:22233296 Breast carcinoma Xist stain—top 20% overexpressed
in positive (Richardson)
3760 2.30E-11 1.77
Oncomine gene expression signatures MCM:22233306 Breast carcinoma HER2/neu status—top 20%
overexpressed in positive (Richardson)
3760 4.20E-11 1.75
Oncomine gene expression signatures MCM:8451682 T98G cells condition—top 10% overexpressed in
growth arrest by serum deprivation (Cam)
1240 8.20E-11 2.16
Literature-defined concepts MCM:121874 Upregulated genes in U937 cells expressing the
PLZF/RAR fusion protein
2265 9.70E-09 1.7674
Chromosome subregion MCM:110293 Xp11 114 2.20E-08 6.2922
Oncomine gene expression signatures MCM:131276 Brain survival—3 yr—top 10% overexpressed
in dead (Shai)
780 2.70E-08 2.2351
Oncomine gene expression signatures MCM:142608 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in c-Src (Bild)
1880 6.60E-08 1.7999
Oncomine gene expression signatures MCM:124888 Acute myeloid leukemia karyotype—top 10%
overexpressed in t(15;17) PML-RARa (Valk)
1240 3.80E-07 1.8709
Connectivity map MCM:21641726 Cell line batch—description—top 5% underexpressed
in 56, PC3 treated with valproic acid (.001 M) for
6 h (Lamb)
620 5.20E-07 2.21
Oncomine gene expression signatures MCM:142662 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in activated
H-Ras (Bild)
1880 6.60E-06 1.6202
Table W5.
Concept type MCM ID Concept No. of Genes
Literature-defined concepts MCM:118121 Downregulated genes in APL patients treated with RA 454
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine gene expression signatures MCM:22235386 Acute myeloid leukemia FAB subtype—top 20%
overexpressed in M3 [acute promyelocytic
leukemia (APL) with t(15;17)] (Gutierrez)
2480 3.30E-66 6.21
Oncomine gene expression signatures MCM:124888 Acute myeloid leukemia karyotype—top 10%
overexpressed in t(15;17) PML-RARa (Valk)
1240 8.40E-51 6.1586
Oncomine gene expression signatures MCM:133688 Kidney type—top 10% overexpressed in renal clear
cell carcinoma (Lenburg)
1720 8.80E-23 3.3833
Oncomine gene expression signatures MCM:126213 Acute lymphoblastic leukemia cytogenetics—top 10%
overexpressed in MLL (Ross)
1720 3.40E-20 3.1769
Connectivity map MCM:21641456 Cell line batch—description—top 5% underexpressed
in 44, HL60 treated with valproic acid (0.01 M) for
6 h (Lamb)
620 5.10E-19 4.31
Oncomine gene expression signatures MCM:121474 Acute lymphoblastic leukemia translocation—top 10%
overexpressed in MLL/AF4 (Fine)
1290 5.40E-19 3.3342
Oncomine gene expression signatures MCM:123019 Acute lymphoblastic leukemia translocation—top 5%
overexpressed in MLL-AF4 (Tsutsumi)
360 3.00E-18 5.4689
Literature-defined concepts MCM:121874 Upregulated genes in U937 cells expressing the
PLZF/RAR fusion protein
2265 1.10E-16 2.6589
Oncomine gene expression signatures MCM:122900 Acute myeloid leukemia FAB classification—top 10%
overexpressed in M3—acute promyelocytic
leukemia (Debernardi)
780 9.80E-15 3.4586
Oncomine gene expression signatures MCM:142607 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in activated
H-Ras (Bild)
1880 1.30E-12 2.4844
Oncomine gene expression signatures MCM:22210186 Diffuse large B-cell lymphoma microarray diagnosis—top
10% overexpressed in activated B cell – like (Dave)
220 1.30E-12 6.05
Oncomine gene expression signatures MCM:142661 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in c-Myc (Bild)
1880 1.40E-12 2.4797
Literature-defined concepts MCM:121872 Upregulated genes in U937 cells expressing the
PML/RAR fusion protein
1142 3.70E-12 2.8409
Connectivity map MCM:21642376 Cell line batch—description—top 5% underexpressed in
75, HL60 treated with 1,5-isoquinolinediol (0.0001 M)
for 6 h (Lamb)
620 5.60E-10 3.01
Connectivity map MCM:21641086 Cell line batch—description—top 5% underexpressed in
35, HL60 treated with LY-294002 (0.00001 M) for
6 h (Lamb)
620 1.70E-09 2.93
Connectivity map MCM:21641336 Cell line batch—description—top 5% underexpressed
in 41, HL60 treated with tretinoin (0.000001 M) for
6 h (Lamb)
620 1.10E-07 2.64
Connectivity map MCM:21639206 MCF cell treatment—top 5% underexpressed in 502,
MCF7 treated with tretinoin (0.000001 M) for
6 h (Lamb)
620 3.00E-07 2.57
Table W6.
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21639806 MCF cell treatment—top 5% underexpressed in 505,
MCF7 treated with wortmannin (.00000001 M) for
6 h (1) vs 505, MCF7 with vehicle (DMSO) for
6 h (6) (Lamb)
620
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:142661 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in c-Myc (Bild)
1880 3.90E-41 3.84
Oncomine MCM:142662 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in activated
H-Ras (Bild)
1880 5.60E-30 3.14
Oncomine MCM:120991 Breast carcinoma disease-free survival—5 yr—top
10% overexpressed in relapse (vandeVijver)
1480 6.70E-30 3.44
Oncomine MCM:142666 Melanoma type—top 10% overexpressed in melanoma
(Talantov)
1240 3.10E-19 2.74
Oncomine MCM:3116782 Sarcoma type—top 10% overexpressed in
leiomyosarcoma (Henderson)
840 3.20E-17 2.97
Oncomine MCM:8463322 Lymphoma Myc fusion—top 10% overexpressed in
IG-Myc (Hummel)
1240 7.20E-16 2.51
Oncomine MCM:22210246 Breast carcinoma p53 mutation status—top 10%
overexpressed in mutated (Miller)
1240 1.80E-15 2.48
Oncomine MCM:8463582 Plasma cell dyscrasia type—top 10% overexpressed
in plasma cell leukemia (Mattioli)
1240 2.70E-14 2.4
Oncomine MCM:7641812 Lymphoma definite Burkitts lymphoma—top 10%
overexpressed in yes (Hummel)
1240 1.00E-11 2.21
Oncomine MCM:5328422 Prostate type—top 10% overexpressed in
hormone-refractory metastatic prostate cancer
tissue (Varambally)
1880 1.30E-11 2.12
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21639486 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with tretinoin (0.000001 M) for 6 h (1)
vs 504, MCF7 with vehicle (DMSO) for 6 h (6) (Lamb)
620
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:142647 Human primary mammary epithelial cells oncogene
transfected—top 5% overexpressed in c-Src (Bild)
940 6.10E-50 5.7
Oncomine MCM:10660996 Pheochromocytoma location—top 10% overexpressed
in paraganglioma (Dahia)
1240 3.80E-36 3.8
Oncomine MCM:142514 Leukemia type—top 5% overexpressed in B-cell acute
lymphoblastic leukemia (Raetz)
620 4.80E-35 5.04
Oncomine MCM:21463136 Brain type—top 10% overexpressed in oligodendroglioma
(Sun)
1880 8.20E-35 3.5
Oncomine MCM:3116702 Sarcoma type—top 10% overexpressed in alveolar
rhabdomyosarcoma (Henderson)
680 2.40E-29 4.32
Oncomine MCM:142662 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in activated
H-Ras (Bild)
1880 6.30E-23 2.75
Oncomine MCM:3116722 Sarcoma type—top 10% overexpressed in chondromyxoid
fibroma (Henderson)
710 3.20E-20 3.43
Oncomine MCM:3116762 Sarcoma type—top 10% overexpressed in embryonal
rhabdomyosarcoma (Henderson)
660 1.60E-16 3.18
Oncomine MCM:22236266 Lung type—top 10% overexpressed in squamous cell
carcinoma (Wachi)
1240 1.80E-15 2.48
Oncomine MCM:117785 Cancer type—top 10% overexpressed in colorectal
adenocarcinoma (Su)
734 6.20E-15 2.85
Oncomine MCM:22211976 Breast carcinoma estrogen receptor status—top 10%
overexpressed in positive (Yu)
884 8.00E-15 2.71
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21639466 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with resveratrol (0.00001 M) for
6 h (1) vs 504, MCF7 with vehicle (DMSO) for
6 h (6) (Lamb)
620
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:131068 Cell line p53 mutation status—top 10% underexpressed
in wild type (Robinson)
1720 8.80E-39 3.97
Oncomine MCM:22208946 Breast carcinoma Elston grade—top 1% overexpressed
in 3 (Miller)
124 1.60E-37 16.27
Table W6. (continued)
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:22208966 Breast carcinoma p53 mutation status—top 1%
overexpressed in mutated (Miller)
124 1.60E-37 16.27
Oncomine MCM:140004 ER+ breast carcinoma disease-free survival—5 yr—top
10% overexpressed in relapse (Wang)
1240 2.60E-37 3.87
Oncomine MCM:114895 Breast carcinoma grade—top 1% overexpressed in
3 (van)
150 3.70E-35 14.73
Oncomine MCM:8467052 Breast carcinoma grade—top 1% overexpressed in
3 (Sotiriou)
124 3.90E-35 15.17
Oncomine MCM:125068 Breast carcinoma disease-free survival—5 yr—top
10% overexpressed in relapse (Wang)
1240 2.70E-33 3.62
Oncomine MCM:22239956 Breast carcinoma grade—top 1% overexpressed
in 3 (Ma)
146 2.40E-30 13.14
Literature-defined MCM:100084 Differentially expressed genes in HeLa cells during
the cell cycle
712 2.50E-27 4.34
Oncomine MCM:7221242 Chronic myelogenous leukemia phase—All—top
10% overexpressed in CD34 (Radich)
1480 2.30E-25 3.2
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21639396 MCF cell treatment—top 5% underexpressed in 504,
MCF7 treated with geldanamycin (0.000001 M) for
6 h (1) vs 504, MCF7 with vehicle (DMSO) for
6 h (6) (Lamb)
620
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:142631 Human primary mammary epithelial cells oncogene
transfected—top 1% overexpressed in c-Src (Bild)
188 1.90E-25 8.43
Oncomine MCM:21463136 Brain type—top 10% overexpressed in oligodendroglioma
(Sun)
1880 3.30E-24 2.89
Oncomine MCM:142485 Leukemia type—top 1% overexpressed in B-cell acute
lymphoblastic leukemia (Raetz)
124 4.50E-21 9.37
Oncomine MCM:123532 Prostate type—top 5% overexpressed in prostate
carcinoma (Yu)
390 8.00E-18 4.21
Oncomine MCM:3116702 Sarcoma type—top 10% overexpressed in alveolar
rhabdomyosarcoma (Henderson)
680 8.90E-18 3.26
Oncomine MCM:125527 Prostate type—top 10% overexpressed in prostate
tumor (Singh)
690 2.40E-16 3.17
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21640116 MCF cell treatment—top 5% underexpressed in 506,
MCF7 treated with valproic acid (0.001 M) for 6 h (1)
vs 506, MCF7 with vehicle (DMSO) for 6 h (6) (Lamb)
620
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:22234846 Bone marrow type—top 10% overexpressed in
smoldering multiple myeloma (Zhan)
1880 1.50E-22 2.78
Oncomine MCM:124891 Acute myeloid leukemia FAB subtype—top 10%
overexpressed in M1 (Valk)
1240 2.80E-16 2.54
Oncomine MCM:125063 Prostate biochemical recurrence—5 yr—top 10%
overexpressed in positive (Glinsky)
1240 1.60E-13 2.35
Oncomine MCM:22210326 Breast carcinoma estrogen receptor status—top
10% overexpressed in positive (Hess)
1240 3.70E-13 2.32
Oncomine MCM:7641812 Lymphoma definite Burkitts lymphoma—top 10%
overexpressed in yes (Hummel)
1240 8.50E-13 2.29
Oncomine MCM:142542 Leukemia type—top 10% overexpressed in
T-cell lymphoblastic lymphoma (Raetz)
1240 2.00E-12 2.27
Oncomine MCM:142606 Human primary mammary epithelial cells
oncogene transfected—top 10% overexpressed
in c-Myc (Bild)
1880 2.90E-12 2.17
Oncomine MCM:8463572 Plasma cell dyscrasia type—top 10% overexpressed
in multiple myeloma (Mattioli)
1240 2.20E-11 2.19
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21641096 Cell line batch—description—top 5% underexpressed
in 35, HL60 treated with sirolimus (0.0000001 M)
for 6 h (1) vs 35, HL60 with vehicle (DMSO) for
6 h (1) (Lamb)
620
Table W6. (continued)
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:8463582 Plasma cell dyscrasia type—top 10% overexpressed
in plasma cell leukemia (Mattioli)
1240 2.00E-22 2.95
Oncomine MCM:142607 Human primary mammary epithelial cells oncogene
transfected—top 10% overexpressed in activated
H-Ras (Bild)
1880 3.20E-12 2.12
Oncomine MCM:8467192 Breast carcinoma survival—5 yr—top 10%
overexpressed in dead (Pawitan)
1720 1.50E-11 2.15
Oncomine MCM:124894 Acute myeloid leukemia FAB subtype—top 10%
overexpressed in M6 (Valk)
1240 2.20E-11 2.19
Oncomine MCM:8467202 Breast carcinoma BRCA1 mutation—top 10%
overexpressed in positive (Pawitan)
1720 3.30E-11 2.14
Oncomine MCM:8456042 Head and neck squamous cell carcinoma
differentiation—top 10% overexpressed in
poor (Ginos)
1240 4.80E-10 2.08
Oncomine MCM:125063 Prostate biochemical recurrence—5 yr—top 10%
overexpressed in positive (Glinsky)
1240 2.10E-09 2.03
Oncomine MCM:22234856 Bone marrow type—top 10% overexpressed in
smoldering multiple myeloma (Zhan)
1880 2.40E-09 1.94
Oncomine MCM:8463402 Colon BRAF mutation status—top 10%
overexpressed in mutant (Koinuma)
1720 2.90E-09 1.97
Concept type MCM ID Concept No. of Genes
Connectivity map MCM:21641146 Cell line batch—description—top 5%
underexpressed in 36, MCF7 treated with
imatinib (0.00001 M) for 6 h (1) vs 36,
MCF7 with vehicle (DMSO) for 6 h (1) (Lamb)
620
Concept type MCM ID Concept No. of Genes P Odds Ratio
Oncomine MCM:22229426 Colon carcinoma Dukes stage—top 10%
overexpressed in C, D (Bittner)
1880 4.80E-11 2.14
Oncomine MCM:131269 Acute myeloid leukemia karyotype—top 10%
overexpressed in 11q23 MLL (Valk)
1240 1.10E-10 2.14
Oncomine MCM:22212046 Acute lymphoblastic leukemia genetic
features—top 10% overexpressed in
BCR-ABL positive (Kirschner-Schwabe)
1240 1.00E-09 2.06
Oncomine MCM:22229406 Colon carcinoma primary/metastasis—top
10% overexpressed in metastasis (Bittner)
1880 1.10E-09 2.06
Oncomine MCM:125063 Prostate biochemical recurrence—5 yr—top
10% overexpressed in positive (Glinsky)
1240 2.10E-09 2.03
Oncomine MCM:142540 Leukemia type—top 10% overexpressed in
B-cell acute lymphoblastic leukemia (Raetz)
1240 4.30E-09 2.01
Oncomine MCM:22231346 Cutaneous melanoma mutation—top 10%
overexpressed in wild type (Hoek)
1240 4.30E-09 2.01
Oncomine MCM:130776 Acute myeloid leukemia FAB subtype—top
10% overexpressed in M0 (Valk)
1240 4.30E-09 2.01
Oncomine MCM:8446172 Pancreatic ductal carcinoma cytological
grade—top 10% overexpressed in V
(Ishikawa)
1720 5.40E-09 1.99
Oncomine MCM:22234956 Acute myeloid leukemia FAB subtype—top
10% overexpressed in M0 [AML minimally
differentiated] (Gutierrez)
1240 8.70E-09 1.98
Significant associations for seven drug signatures are provided. The query molecular concept is listed first, followed by selected molecular concepts that were
significantly associated with the query concept. Each analysis is separated by two lines.
